News

23 March 2020

CORONAVIRUS - DiaSorin COVID-19 test has received FDA Emergency Use Authorization

DiaSorin Molecular LLC, a division of DiaSorin S.p.A. announced that it has received Emergency Use Authorization (EUA) from the FDA for their Simplexa™ COVID-19 Direct kit.
21 March 2020

CORONAVIRUS - Takis announces that it is ready to test its Covid-19 vaccine on pre-clinical models

The authorization comes from the Ministry of Health and represents the first step in bringing the vaccine to human use. Takis researchers are the only ones in Italy and the first in Europe to access this phase of the experimentation.
10 March 2020

CORONAVIRUS - DiaSorin has completed the studies to support the launch by the end of march 2020 of a rapid response molecular diagnostic test for the COVID-19

DiaSorin announced that it has completed at the Spallanzani Hospital in Rome and at the Policlinico San Matteo in Pavia, the studies necessary to support the CE marking and FDA EUA submission of an innovative molecular test for the rapid identification of the novel coronavirus COVID-19.
03 March 2020

CORONAVIRUS - Applied DNA Sciences updates on COVID-19 collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine candidates designed

Applied DNA Sciences Inc. and Takis Biotech announced that the design of 4 DNA vaccine candidates that will be produced for preclinical animal testing via the Company’s proprietary PCR-based DNA manufacturing systems
10 February 2020

CORONAVIRUS - The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine

The Jenner Institute, Oxford University, UK and Advent Srl – an IRBM company, Pomezia,Italy – are continuing their long-standing history of collaboration, by announcing a new agreement to develop a novel vaccine for coronavirus.
04 February 2020

CORONAVIRUS - Takis and Evvivax developing a 2019-nCoV Coronavirus vaccine

Takis and Evvivax, two biotechnology companies present in the science park of Castel Romano, Rome announce their commitment for the development of innovative vaccines against 2019-nCoV

Where to find us

20149 Milan
Via Giovanni da Procida, 11
Show map 
Tel. +39 02.34565.1
Fax. +39 02.34565.310
Segreteria Assobiotec
Tel. 02 34565.256/341
assobiotec@federchimica.it